JP2024526742A5 - - Google Patents
Info
- Publication number
- JP2024526742A5 JP2024526742A5 JP2024501754A JP2024501754A JP2024526742A5 JP 2024526742 A5 JP2024526742 A5 JP 2024526742A5 JP 2024501754 A JP2024501754 A JP 2024501754A JP 2024501754 A JP2024501754 A JP 2024501754A JP 2024526742 A5 JP2024526742 A5 JP 2024526742A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- weeks
- composition according
- ravulizumab
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221826P | 2021-07-14 | 2021-07-14 | |
| US63/221,826 | 2021-07-14 | ||
| US202163276271P | 2021-11-05 | 2021-11-05 | |
| US63/276,271 | 2021-11-05 | ||
| PCT/US2022/037147 WO2023287991A1 (en) | 2021-07-14 | 2022-07-14 | Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024526742A JP2024526742A (ja) | 2024-07-19 |
| JP2024526742A5 true JP2024526742A5 (https=) | 2025-07-23 |
Family
ID=83004487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024501754A Pending JP2024526742A (ja) | 2021-07-14 | 2022-07-14 | 重症筋無力症の治療のための抗ｃ５抗体の投与量及び投与 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250154232A1 (https=) |
| EP (1) | EP4370547A1 (https=) |
| JP (1) | JP2024526742A (https=) |
| WO (1) | WO2023287991A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| EP3924380A1 (en) * | 2019-02-14 | 2021-12-22 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis |
-
2022
- 2022-07-14 US US18/577,912 patent/US20250154232A1/en active Pending
- 2022-07-14 EP EP22757718.6A patent/EP4370547A1/en active Pending
- 2022-07-14 JP JP2024501754A patent/JP2024526742A/ja active Pending
- 2022-07-14 WO PCT/US2022/037147 patent/WO2023287991A1/en not_active Ceased